Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Epoetin Hospira SDV · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Epoetin Hospira SDV | EXPERIMENTAL | Epoetin Hospira Single Dose Vial (SDV) |
| Epoetin Hospira MDV | EXPERIMENTAL | Epoetin Hospira Multi-Dose Vial (MDV) |
| Name | Type | Description |
|---|---|---|
| Epoetin Hospira SDV | DRUG | Epoetin Hospira Single Dose Vial |
| Epoetin Hospira MDV | DRUG | Epoetin Hospira Multi-Dose Vial |
Inclusion Criteria: 1. Healthy female and male subjects who, at time of Screening, are between ages of 18 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination including blood pressure and pulse rate m...
Epoetin Hospira SDV is an investigational erythropoiesis-stimulating agent developed by Pfizer, Inc. (NYSE: PFE). It is a single-dose vial formulation of epoetin. The specific clinical indication for this product has not been publicly disclosed. It is in Phase 1 clinical development.
Epoetin Hospira SDV targets the erythropoietin receptor (EPOR), where it acts as an agonist. By binding to and activating EPOR, it mimics the action of endogenous erythropoietin, the hormone that regulates red blood cell production. This mechanism is characteristic of erythropoiesis-stimulating agents.
Epoetin Hospira SDV is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer is the company responsible for the clinical development of this single-dose vial formulation of epoetin.
Epoetin Hospira SDV is in Phase 1 clinical development. It is an investigational product and has not been approved by the FDA. The Phase 1 program consists of one completed trial that enrolled 68 healthy volunteers.
Epoetin Hospira SDV has been studied in one completed Phase 1 trial, NCT03398473. The trial compared the effects of the single-dose vial and multi-dose vial formulations when administered subcutaneously to normal healthy subjects. It enrolled 68 participants in the United States and was randomized and controlled.
Epoetin Hospira SDV is a specific single-dose vial formulation of epoetin developed by Pfizer. It is distinct from other epoetin products and formulations. The trial NCT03398473 specifically compared the single-dose vial (SDV) and multi-dose vial (MDV) presentations of Epoetin Hospira.